Search · four archives
Search · four archives
18 papers · ranked by Valyu relevance
Taylor C. Peak, Elena M. Fenu, Michael B. Rothberg, Christopher Y. Thomas + 2 more
'Christopher Y. Thomas' 'Ronald L. Davis' 'Edward A. Levine'] Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to…
Kavin Sugumar, Jessica Jin Lie, Chee-Chee Stucky, Yu-Hui Chang + 7 more
Clinical end points are used to assess the effectiveness of novel cancer therapies.1 Overall survival (OS) is considered the reference standard end point for estimating long-term efficacy in oncologic drug development,2 but measuring OS can be expensive and time-consuming and lacks information on quality of life and…
Hongyi Duanmu, Shristi Bhattarai, Hongxiao Li, Shi Zhan + 8 more
Predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients accurately is direly needed for clinical decision making. pCR is also regarded as a strong predictor of overall survival. In this work, we propose a deep learning system to predict pCR to…
Alexandre Gheller, Guilherme Inácio Bertoldo de Melo e Patriarca da Silva Neiva, Mario Nóbrega de Araújo Neto, Fernando Gonçalves Lyrio + 5 more
'Guilherme Inácio Bertoldo de Melo e Patriarca da Silva Neiva' 'Mario Nóbrega de Araújo Neto' 'Fernando Gonçalves Lyrio' 'Dunya Bachour Basílio' 'Marília Cristina Roda da Costa' 'Douglas Vieira Mourão' 'Paulo Gonçalves de Oliveira' 'João Batista de Sousa'] Title: Highlights 1. • Correlation between pathologic complete…
Chi-en Amy Tai, Alexander Wong
Imaging to Enhance Breast Cancer Pathologic Complete Response Prediction Authors: ['Chi-en Amy Tai' 'Alexander Wong'] In 2020, 685,000 deaths across the world were attributed to breast cancer, underscoring the critical need for innovative and effective breast cancer treatment. Neoadjuvant chemotherapy has recently…
Hanano Ando, Yuki Katoh, Osamu Kobayashi, Yuji Ikeda + 20 more
Among 42 patients in whom high-dose IGMKKE7 was orally administered, 11 and 31 patients were diagnosed as having CIN-2 and CIN-3, respectively; 31% (13/42) of patients with CIN-2/3 were positive for HPV-16 only, and the remaining 29 patients (69%) were positive for HPV-16 and other HPV genotypes. In the MILACLE study…
Kei Kawana, Osamu Kobayashi, Yuji Ikeda, Hideaki Yahata + 19 more
The study was designed to have 80% power to detect a 30%, 20%, and 10% difference in the rates of pathological complete regression or complete regression plus partial regression between high-, intermediate-, low-dose, and placebo groups, respectively. Because spontaneous regression to normal or CIN 1 with placebo was…
Stefan Schliep, Abbas Agaimy, Alexander Cavallaro, Franklin Kiesewetter + 2 more
'Franklin Kiesewetter' 'Gerold Schuler' 'Lucie Heinzerling'] Background The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first time that patients were completely free of…
Hikmat Khan, Ziyu Su, Huina Zhang, Yihong Wang + 5 more
'Shi Wei' 'Hua Guo' 'Zaibo Li' 'Muhammad Khalid Khan Niazi'] Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) expression, resulting in limited targeted treatment options.…
Martin L Ashdown, Brendon J Coventry, Derek Abbott
Introduction Recent evidence suggests that the failure of the immune system to eradicate cancer cells is due to the tumor co-opting the normal regulatory/suppressive and homeostatic mechanisms of the immune system, thus avoiding immune based destruction. A small percentage of patients with complete responses (CR; no…
Shristi Bhattarai, Geetanjali Saini, Hongxiao Li, Hongyi Duanmu + 6 more
Neoadjuvant chemotherapy (NAC) is the standard treatment for early-stage triple negative breast cancer (TNBC). The primary endpoint of NAC is a pathological complete response (pCR). NAC results in pCR in only 30%–40% of TNBC patients. Tumor-infiltrating lymphocytes (TILs), Ki67 and phosphohistone H3 (pH3) are a few…
Marta Bofill Roig, Yu Shen, Guadalupe Gómez Melis
Pathologic complete response (pCR) is a common primary endpoint for a phase II trial or even accelerated approval of neoadjuvant cancer therapy. If granted, a two-arm confirmatory trial is often required to demonstrate the efficacy with a time-to-event outcome such as overall survival. However, the design of a…
Aya Ludin, Georgia L. Stirtz, Asaf Tal, Ajit J. Nirmal + 35 more
Immunotherapy leads to cancer eradication despite the tumor’s immunosuppressive environment. Here, we used extended long-term in-vivo imaging and high-resolution spatial transcriptomics of endogenous melanoma in zebrafish, and multiplex imaging of human melanoma, to identify domains that facilitate immune response…
Iago De Castro Silva, Prateek Sharma, Anna Bianchi, Nilesh U. Deshpande + 6 more
Partial/complete pathologic response following neoadjuvant chemotherapy (NAC) in pancreatic cancer (PDAC) patients undergoing pancreatectomy is associated with improved survival. We sought to determine whether neutrophil-to-lymphocyte ratio (NLR) dynamics predict pathologic response following chemotherapy in PDAC, and…
Zahra Rahimi Afzal, Wataru Uegami, Saghir Alfasly, Saba Yasir + 4 more
Digital pathology archives increasingly contain multiple whole-slide images (WSIs) per case, capturing spatially distinct tumour regions and reflecting intrinsic morphological heterogeneity. However, most existing approaches rely on a single pathologist-selected slide, thereby discarding potentially informative…
Collin Y. Zheng, Peter Kim
We introduce a set of ordinary differential equations (ODE) that qualitatively reproduces delayed responses observed in immune checkpoint blockade therapy (e.g. anti-CTLA-4 Ipilimumab). This type of immunotherapy has been at the forefront of novel and promising cancer treatments over the past decade and was recognised…
Liping Zhang, Ben Zhong Tang, Zheng Zhao, Yu Xiong + 8 more
Targeted and controllable drug release at lesion sites with the aid of visual navigation in real-time is of great significance for precise theranostics of cancers. Benefiting from the marvellous features (e.g. bright emission and phototheranostic effect in aggregates) of aggregation-induced emission (AIE) materials…
Soren Ghorai, Ashley Pearson
Chimeric antigen receptor T (CAR-T) cell therapy has transformed the field of immunology by redirecting T lymphocytes toward tumor antigens. Despite successes in attaining remission rates as high as 70%, the performance of CAR therapy is limited by the survival of T cells. T cell persistence is crucial as it sustains…